Clinical Trial

DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy

Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the efficacy and safety of Disitamab Vedotin Combined with Cadonilimab in subjects with HER2-expressing locally advanced or metastatic gastric cancer and gastroesophageal junction adenocarcinoma after progression on first-line therapy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-01-15.
Status change: Not Yet Recruiting → Recruiting 2024-04-01
Trial Details
NCT Number NCT06221748
Lead Sponsor RemeGen Co., Ltd.
Conditions Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Enrollment 90 participants
Start Date 2024-02-22
Primary Completion 2026-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2024-04-03